Literature DB >> 19124661

Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.

Vidhya Prakash1, James S Lewis, Monica L Herrera, Brian L Wickes, James H Jorgensen.   

Abstract

Effective therapeutic options are needed for community-onset urinary tract infections due to Escherichia coli strains that produce CTX-M extended-spectrum beta-lactamases. We examined 46 urinary isolates producing CTX-M against several oral or long-acting parenteral antimicrobial agents. Approximately 90% were susceptible to fosfomycin and to a combination of cefdinir plus amoxicillin-clavulanate. All were susceptible to ertapenem.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19124661      PMCID： PMC2650586          DOI： 10.1128/AAC.01519-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.

Authors:  L A Miller; K Ratnam; D J Payne
Journal:  Curr Opin Pharmacol       Date:  2001-10       Impact factor: 5.547

2.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  Arch Intern Med       Date:  2008-09-22

3.  Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.

Authors:  Husnu Pullukcu; Meltem Tasbakan; Oguz Resat Sipahi; Tansu Yamazhan; Sohret Aydemir; Sercan Ulusoy
Journal:  Int J Antimicrob Agents       Date:  2007-01       Impact factor: 5.283

4.  In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.

Authors:  Kwan Soo Ko; Ji Yoeun Suh; Kyong Ran Peck; Mi Young Lee; Won Sup Oh; Ki Tae Kwon; Dong Sik Jung; Nam Yong Lee; Jae-Hoon Song
Journal:  Diagn Microbiol Infect Dis       Date:  2007-02-14       Impact factor: 2.803

5.  Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women.

Authors:  P L Ho; Winnie W N Poon; S L Loke; Marianne S T Leung; K H Chow; River C W Wong; K S Yip; Eileen L Lai; Kenneth W T Tsang
Journal:  J Antimicrob Chemother       Date:  2007-05-11       Impact factor: 5.790

6.  Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates.

Authors:  Johann D D Pitout; Deirdre L Church; Daniel B Gregson; Barbara L Chow; Melissa McCracken; Michael R Mulvey; Kevin B Laupland
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

7.  Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?

Authors:  B J Knottnerus; S Nys; G Ter Riet; G Donker; S E Geerlings; E Stobberingh
Journal:  J Antimicrob Chemother       Date:  2008-04-19       Impact factor: 5.790

8.  First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.

Authors:  James S Lewis; Monica Herrera; Brian Wickes; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

9.  Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  C-I Kang; H S Cheong; D R Chung; K R Peck; J-H Song; M-D Oh; K-W Choe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-18       Impact factor: 3.267

10.  Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.

Authors:  J Tamayo; B Orden; J Cacho; J Cuadros; J L Gomez-Garces; J I Alos
Journal:  Rev Esp Quimioter       Date:  2007-09       Impact factor: 1.553
View more
  20 in total

1.  Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae.

Authors:  Jennifer D Campbell; James S Lewis; M Leticia McElmeel; Letitia C Fulcher; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

2.  Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.

Authors:  Vidhya Prakash; James S Lewis; Monica L Herrera; Brian L Wickes; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

3.  Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.

Authors:  Si-Ho Kim; Kyoung Ree Lim; Hyunju Lee; Kyungmin Huh; Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Kyong Ran Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-13       Impact factor: 3.267

4.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

5.  In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.

Authors:  M Tärnberg; A Ostholm-Balkhed; H-J Monstein; A Hällgren; H Hanberger; L E Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-06       Impact factor: 3.267

6.  Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.

Authors:  James Cohen Stuart; Maurine Leverstein-Van Hall; Willemijn Kortmann; J Verlind; Frouke Mulder; Jelle Scharringa; Ad Fluit; Miquel Ekkelenkamp
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-16       Impact factor: 3.267

7.  In Vivo Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model.

Authors:  Kamilia Abdelraouf; Sean M Stainton; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

8.  Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants during hospitalization in neonatal intensive care unit (NICU).

Authors:  Polly Soo Xi Yap; Azanna Ahmad Kamar; Chun Wie Chong; Ivan Kok Seng Yap; Kwai Lin Thong; Yao Mun Choo; Mohd Yasim Md Yusof; Cindy Shuan Ju Teh
Journal:  Pathog Glob Health       Date:  2016-09-21       Impact factor: 2.894

9.  Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and Coresistance phenotype among recent Escherichia coli isolates from U.S. veterans.

Authors:  James R Johnson; Sarah M Drawz; Stephen Porter; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

Review 10.  Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems.

Authors:  Bradley J Gardiner; Andrew J Stewardson; Iain J Abbott; Anton Y Peleg
Journal:  Aust Prescr       Date:  2019-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.